89 related articles for article (PubMed ID: 26141305)
1. Efficacy and Safety of Pergoveris in Assisted Reproductive Technology--ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment.
Humaidan P; Schertz J; Fischer R
BMJ Open; 2015 Jul; 5(7):e008297. PubMed ID: 26141305
[TBL] [Abstract][Full Text] [Related]
2. Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation.
Koloda Y; Korsak V; Rozenson O; Anshina M; Sagamonova K; Baranov I; Yakovenko S; D'Hooghe T; Ershova A; Lispi M
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):134-148. PubMed ID: 35216907
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Reprod Biomed Online; 2024 Jun; 48(6):103725. PubMed ID: 38593745
[TBL] [Abstract][Full Text] [Related]
4. Comparison of DNA damage in granulosa cells of women undergoing controlled ovarian stimulation in in vitro fertilization protocols with the recombinant human follicle-stimulating hormones Corneumon
Alcalá-Sánchez X; Cuapio-Padilla P; Salazar-López C; Rodríguez R; Teteltitla M; Bahena I; Betancourt M; Casas E; Casillas F; López A; Bonilla E
Arch Gynecol Obstet; 2024 May; 309(5):2107-2114. PubMed ID: 38441601
[TBL] [Abstract][Full Text] [Related]
5. Use of platelet-rich plasma in the treatment of infertility in poor responders in assisted human reproduction procedures.
Pacu I; Zygouropoulos N; Dimitriu M; Rosu G; Ionescu CA
Exp Ther Med; 2021 Dec; 22(6):1412. PubMed ID: 34676005
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS).
Grynberg M; Cedrin-Durnerin I; Raguideau F; Herquelot E; Luciani L; Porte F; Verpillat P; Helwig C; Schwarze JE; Paillet S; Castello-Bridoux C; D'Hooghe T; Benchaïb M
Best Pract Res Clin Obstet Gynaecol; 2023 Jun; 88():102308. PubMed ID: 36707343
[TBL] [Abstract][Full Text] [Related]
7. Reply of the Authors: Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection.
Witz CA; Doody KJ; Park JK; Daftary GS; Heiser PW
Fertil Steril; 2024 Feb; 121(2):359. PubMed ID: 37995797
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
9. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
Nyboe Andersen A; Nelson SM; Fauser BC; García-Velasco JA; Klein BM; Arce JC;
Fertil Steril; 2017 Feb; 107(2):387-396.e4. PubMed ID: 27912901
[TBL] [Abstract][Full Text] [Related]
10. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.
Al-Inany HG; Youssef MA; Ayeleke RO; Brown J; Lam WS; Broekmans FJ
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD001750. PubMed ID: 27126581
[TBL] [Abstract][Full Text] [Related]
11. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction.
Nagels HE; Rishworth JR; Siristatidis CS; Kroon B
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009749. PubMed ID: 26608695
[TBL] [Abstract][Full Text] [Related]
12. Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population.
Revelli A; Pettinau G; Basso G; Carosso A; Ferrero A; Dallan C; Canosa S; Gennarelli G; Guidetti D; Filippini C; Benedetto C
Reprod Biol Endocrinol; 2015 Jul; 13():77. PubMed ID: 26209525
[TBL] [Abstract][Full Text] [Related]
13. Endometrial injury for pregnancy following sexual intercourse or intrauterine insemination.
Lensen SF; Manders M; Nastri CO; Gibreel A; Martins WP; Templer GE; Farquhar C
Cochrane Database Syst Rev; 2016 Jun; (6):CD011424. PubMed ID: 27296541
[TBL] [Abstract][Full Text] [Related]
14. Ovarian Stimulation Protocol in IVF: An Up-to-Date Review of the Literature.
Pacchiarotti A; Selman H; Valeri C; Napoletano S; Sbracia M; Antonini G; Biagiotti G; Pacchiarotti A
Curr Pharm Biotechnol; 2016; 17(4):303-15. PubMed ID: 26775651
[TBL] [Abstract][Full Text] [Related]
15. In vitro fertilisation for unexplained subfertility.
Pandian Z; Gibreel A; Bhattacharya S
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD003357. PubMed ID: 26583517
[TBL] [Abstract][Full Text] [Related]
16. Corifollitropin alfa followed by hpHMG in GnRH agonist protocols. Two prospective feasibility studies in poor ovarian responders.
Polyzos NP; Corona R; Van De Vijver A; Blockeel C; Drakopoulos P; Vloeberghs V; De Vos M; Camus M; Humaidan P; Tournaye H
Gynecol Endocrinol; 2015; 31(11):885-90. PubMed ID: 26172925
[TBL] [Abstract][Full Text] [Related]
17. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
Mochtar MH; Danhof NA; Ayeleke RO; Van der Veen F; van Wely M
Cochrane Database Syst Rev; 2017 May; 5(5):CD005070. PubMed ID: 28537052
[TBL] [Abstract][Full Text] [Related]
18. A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome.
Lehert P; Arvis P; Avril C; Massin N; Parinaud J; Porcu G; Rongières C; Sagot P; Wainer R; D'Hooghe T
Hum Reprod; 2021 May; 36(6):1600-1610. PubMed ID: 33860313
[TBL] [Abstract][Full Text] [Related]
19. Open-Label, Randomized, Two-Way, Crossover Study Assessing the Bioequivalence of the Liquid Formulation versus the Freeze-Dried Formulation of Recombinant Human FSH and Recombinant Human LH in a Fixed 2:1 Combination (Pergoveris
Bagchus W; Yalkinoglu Ö; Wolna P
Front Endocrinol (Lausanne); 2017; 8():371. PubMed ID: 29375477
[TBL] [Abstract][Full Text] [Related]
20. Recombinant follicular stimulating hormone plus recombinant luteinizing hormone versus human menopausal gonadotropins- does the source of LH bioactivity affect ovarian stimulation outcome?
Kirshenbaum M; Gil O; Haas J; Nahum R; Zilberberg E; Lebovitz O; Orvieto R
Reprod Biol Endocrinol; 2021 Dec; 19(1):182. PubMed ID: 34886872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
